JBIO vs KALA

Jade Biosciences, Inc. vs KALA BIO, Inc. — Valuation Comparison 2026

JBIO

Pharmaceutical Preparations
Jade Biosciences, Inc.
Quality
4.1
out of 10
Value Trap
24
SAFE
Price
$21.04
Last close
Models
7/13
Active
VS

KALA

Pharmaceutical Preparations
KALA BIO, Inc.
Quality
3.3
out of 10
Value Trap
24
SAFE
Price
$2.23
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType JBIO Fair ValueJBIO Upside KALA Fair ValueKALA Upside
Bayesian DCF Intrinsic $6.33 -69.9% $0.06 -97.4%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $3.86 -81.7% $4.24 +89.9%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for JBIO vs KALA — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

JBIO vs KALA — Which Stock Is More Undervalued?

JBIO scores higher with a 4.1/10 quality rating vs KALA's 3.3/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Jade Biosciences, Inc. (JBIO) and KALA BIO, Inc. (KALA) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

JBIO currently trades at $21.04 with a QOC of 4.1/10, while KALA trades at $2.23 with a QOC of 3.3/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).